688192 迪哲医药-U
交易中 10-14 09:51:16
资讯
新帖
简况
迪哲医药（688192）10月13日主力资金净买入348.45万元
证券之星 · 08:14
迪哲医药（688192）10月13日主力资金净买入348.45万元
迪哲医药（688192）9月24日主力资金净卖出1437.14万元
证券之星 · 09-25
迪哲医药（688192）9月24日主力资金净卖出1437.14万元
每周股票复盘：迪哲医药（688192）比瑞替尼治疗DLBCL客观缓解率达47.6%
证券之星 · 09-13
每周股票复盘：迪哲医药（688192）比瑞替尼治疗DLBCL客观缓解率达47.6%
迪哲医药（688192）披露比瑞替尼治疗弥漫性大B细胞淋巴瘤研究成果获《血液肿瘤期刊》发表，9月10日股价下跌0.95%
证券之星 · 09-10
迪哲医药（688192）披露比瑞替尼治疗弥漫性大B细胞淋巴瘤研究成果获《血液肿瘤期刊》发表，9月10日股价下跌0.95%
迪哲医药(688192.SH)：比瑞替尼治疗弥漫性大B细胞淋巴瘤研究成果获《血液肿瘤期刊》发表
智通财经 · 09-09
迪哲医药(688192.SH)：比瑞替尼治疗弥漫性大B细胞淋巴瘤研究成果获《血液肿瘤期刊》发表
每周股票复盘：迪哲医药（688192）舒沃哲一线治疗肺癌适应症获FDA受理
证券之星 · 09-06
每周股票复盘：迪哲医药（688192）舒沃哲一线治疗肺癌适应症获FDA受理
迪哲医药(688192.SH)：与阿斯利康就舒沃哲®授权许可协议生效
智通财经 · 09-01
迪哲医药(688192.SH)：与阿斯利康就舒沃哲®授权许可协议生效
迪哲医药（688192）披露舒沃哲新增适应症上市申请获美国FDA受理，8月31日股价下跌0.66%
证券之星 · 08-31
迪哲医药（688192）披露舒沃哲新增适应症上市申请获美国FDA受理，8月31日股价下跌0.66%
迪哲医药(688192.SH)重新向香港联交所递交H股发行上市申请并刊发申请资
智通财经 · 08-28
迪哲医药(688192.SH)重新向香港联交所递交H股发行上市申请并刊发申请资
每周股票复盘：迪哲医药（688192）股东户数增18.73%
证券之星 · 08-23
每周股票复盘：迪哲医药（688192）股东户数增18.73%
迪哲医药（688192）披露舒沃哲两项非小细胞肺癌临床研究数据获选2026年世界肺癌大会展示，8月21日股价下跌5.07%
证券之星 · 08-21
迪哲医药（688192）披露舒沃哲两项非小细胞肺癌临床研究数据获选2026年世界肺癌大会展示，8月21日股价下跌5.07%
每周股票复盘：迪哲医药（688192）拟调整董事会人数至7人
证券之星 · 08-16
每周股票复盘：迪哲医药（688192）拟调整董事会人数至7人
迪哲医药（688192）披露召开2026年第三次临时股东会的通知，8月4日股价上涨1.68%
证券之星 · 08-04
迪哲医药（688192）披露召开2026年第三次临时股东会的通知，8月4日股价上涨1.68%
每周股票复盘：迪哲医药（688192）与阿斯利康签署授权许可协议
证券之星 · 08-02
每周股票复盘：迪哲医药（688192）与阿斯利康签署授权许可协议
迪哲医药（688192）披露与阿斯利康签署授权许可协议暨关联交易议案获通过，7月30日股价下跌4.07%
证券之星 · 07-30
迪哲医药（688192）披露与阿斯利康签署授权许可协议暨关联交易议案获通过，7月30日股价下跌4.07%
每周股票复盘：迪哲医药（688192）获6亿美元首付款
证券之星 · 07-26
每周股票复盘：迪哲医药（688192）获6亿美元首付款
迪哲医药(688192.SH)发预亏，预计半年度归母净亏损2.1亿元左右
智通财经 · 07-23
迪哲医药(688192.SH)发预亏，预计半年度归母净亏损2.1亿元左右
新股消息 | 迪哲医药(688192.SH)港股IPO招股书失效
智通财经 · 07-23
新股消息 | 迪哲医药(688192.SH)港股IPO招股书失效
迪哲医药（688192）披露拟与阿斯利康签署舒沃哲®全球许可协议，7月22日股价下跌1.49%
证券之星 · 07-22
迪哲医药（688192）披露拟与阿斯利康签署舒沃哲®全球许可协议，7月22日股价下跌1.49%
每周股票复盘：迪哲医药（688192）与阿斯利康签6亿美元协议
证券之星 · 07-19
每周股票复盘：迪哲医药（688192）与阿斯利康签6亿美元协议
加载更多
公司概况
公司名称：
迪哲(江苏)医药股份有限公司
所属行业：
医药制造业
上市日期：
2021-12-10
主营业务：
迪哲(江苏)医药股份有限公司的主营业务是专注于肿瘤、血液系统疾病领域创新疗法的研究、开发和商业化。公司的主要产品是舒沃哲、高瑞哲。公司获第七批国家级专精特新“小巨人”企业认定。此外，公司首款源头创新产品舒沃哲的研发及产业化项目，荣获江苏省科技进步奖一等奖。
发行价格：
52.58
{"stockData":{"symbol":"688192","market":"SH","secType":"STK","nameCN":"迪哲医药-U","latestPrice":61.27,"timestamp":1791942676000,"preClose":61.9,"halted":0,"volume":1264170,"delay":0,"changeRate":-0.0102,"floatShares":461000000,"shares":465000000,"eps":-1.2836,"marketStatus":"交易中","change":-0.63,"latestTime":"10-14 09:51:16","open":61.74,"high":62.04,"low":60.62,"amount":77593200,"amplitude":0.0229,"askPrice":61.26,"askSize":14,"bidPrice":61.25,"bidSize":2,"shortable":0,"etf":0,"ttmEps":-1.2836,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1791948600000},"marketStatusCode":2,"adr":0,"adjPreClose":61.9,"symbolType":"stock_kcb","openAndCloseTimeList":[[1791941400000,1791948600000],[1791954000000,1791961200000]],"highLimit":68.09,"lowLimit":55.71,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":465165842,"isCdr":false,"pbRate":25.48,"roa":"--","roe":"--","epsLYR":-1.71,"committee":0.134021,"marketValue":28501000000,"turnoverRate":0.0027,"status":1,"floatMarketCap":28259000000},"requestUrl":"/m/hq/s/688192","defaultTab":"news","newsList":[{"id":"2675951673","title":"迪哲医药（688192）10月13日主力资金净买入348.45万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675951673","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675951673?lang=zh_cn&edition=full","pubTime":"2026-10-14 08:14","pubTimestamp":1791936846,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月13日收盘，迪哲医药报收于61.9元，上涨7.76%，换手率2.03%，成交量9.37万手，成交额5.64亿元。近5日资金流向一览见下表：迪哲医药融资融券信息显示，融资方面，当日融资买入2281.94万元，融资偿还3997.64万元，融资净偿还1715.7万元。迪哲医药主营业务：专注于肿瘤及血液系统疾病领域创新疗法的研究、开发和商业化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400006914.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK0239","688192","159938","BK1161","09939","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670419940","title":"迪哲医药（688192）9月24日主力资金净卖出1437.14万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670419940","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670419940?lang=zh_cn&edition=full","pubTime":"2026-09-25 08:23","pubTimestamp":1790295809,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月24日收盘，迪哲医药报收于56.45元，下跌6.31%，换手率1.41%，成交量6.52万手，成交额3.74亿元。近5日资金流向一览见下表：迪哲医药融资融券信息显示，融资方面，当日融资买入2711.56万元，融资偿还3926.96万元，融资净偿还1215.39万元。迪哲医药主营业务：专注于肿瘤及血液系统疾病领域创新疗法的研究、开发和商业化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092500005096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK1515","09939","BK0239","BK1161","159938","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667507699","title":"每周股票复盘：迪哲医药（688192）比瑞替尼治疗DLBCL客观缓解率达47.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667507699","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667507699?lang=zh_cn&edition=full","pubTime":"2026-09-13 02:02","pubTimestamp":1789236137,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，迪哲医药报收于53.07元，较上周的57.07元下跌7.01%。本周，迪哲医药9月7日盘中最高价报57.85元。本周关注点公司公告汇总：比瑞替尼治疗r/r DLBCL的II期临床研究结果显示整体客观缓解率达47.6%。公司公告汇总迪哲医药自愿披露，其自主研发的全球首创LYN/BTK双靶点抑制剂比瑞替尼单药治疗复发/难治弥漫性大B细胞淋巴瘤的II期临床研究结果已在《血液肿瘤期刊》发表。安全性方面可控，未报告药物相关的大出血或房颤事件。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK1161","BK0239","BK1515","159938","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666561405","title":"迪哲医药（688192）披露比瑞替尼治疗弥漫性大B细胞淋巴瘤研究成果获《血液肿瘤期刊》发表，9月10日股价下跌0.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666561405","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666561405?lang=zh_cn&edition=full","pubTime":"2026-09-10 17:32","pubTimestamp":1789032727,"startTime":"0","endTime":"0","summary":"截至2026年9月10日收盘，迪哲医药报收于54.38元，较前一交易日下跌0.95%，最新总市值为252.96亿元。该股当日开盘54.92元，最高55.45元，最低53.71元，成交额达1.79亿元，换手率为0.71%。迪哲（江苏）医药股份有限公司于近日披露公告，其自主研发的全球首创LYN/BTK双靶点抑制剂比瑞替尼单药治疗复发/难治弥漫性大B细胞淋巴瘤的II期临床研究结果已在国际权威期刊《血液肿瘤期刊》发表。安全性可控，未报告药物相关的大出血或房颤事件。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000031585.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","159938","BK0239","BK1161","BK1574","09939","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666583145","title":"迪哲医药(688192.SH)：比瑞替尼治疗弥漫性大B细胞淋巴瘤研究成果获《血液肿瘤期刊》发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2666583145","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666583145?lang=zh_cn&edition=full","pubTime":"2026-09-09 15:56","pubTimestamp":1788940569,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药 发布公告，公司自主研发的全球首创、可完全穿透血脑屏障的非共价LYN/BTK双靶点抑制剂比瑞替尼单药治疗复发/难治弥漫性大B细胞淋巴瘤II期临床研究结果正式发表于国际权威血液学期刊《血液肿瘤期刊》。TAI-SHAN9研究入组患者既往接受过1至5线系统性治疗。研究结果显示，在50mg和75mg剂量下，比瑞替尼单药治疗在不同分子亚型中均展现出广谱的抗肿瘤活性，并呈现出可管理的安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1515","09939","BK0239","688192","BK1161","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665567365","title":"每周股票复盘：迪哲医药（688192）舒沃哲一线治疗肺癌适应症获FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2665567365","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665567365?lang=zh_cn&edition=full","pubTime":"2026-09-06 01:30","pubTimestamp":1788629429,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，迪哲医药报收于57.07元，较上周的58.67元下跌2.73%。本周，迪哲医药9月3日盘中最高价报60.69元。本周关注点来自公司公告汇总：舒沃哲新增适应症上市申请获美国FDA受理，拟用于一线治疗EGFR exon20ins非小细胞肺癌。此前，舒沃哲已获中美两国突破性疗法认定，并已在中美获批用于二线及后线治疗。迪哲医药与阿斯利康签署的《许可协议》已于2026年8月31日正式生效，授权阿斯利康在全球范围内独家开发和商业化舒沃哲。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600000251.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK0239","BK1161","09939","BK1574","688192","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664881161","title":"迪哲医药(688192.SH)：与阿斯利康就舒沃哲®授权许可协议生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2664881161","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664881161?lang=zh_cn&edition=full","pubTime":"2026-09-01 08:44","pubTimestamp":1788223497,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)发布公告，公司于2026年7月14日与AstraZeneca UK Limited(以下简称“阿斯利康”)签署《许可协议》，授予阿斯利康在全球范围内独家开发、商业化舒沃哲®的权利。协议约定的协议生效条件已全部满足，协议于2026年8月31日正式生效。阿斯利康将于今年第四季度在美国实现舒沃哲®商业化。公司将获得阿斯利康支付的一次性、不可返还的首付款6亿美元，最高达4 亿美元的临床开发里程碑款项以及最高达5亿美元的销售里程碑款项，此外公司将获得按舒沃哲®全球销售额最高到低双位数的阶梯式比例的特许权使用费。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK0239","BK1161","09939","BK1574","688192","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663071350","title":"迪哲医药（688192）披露舒沃哲新增适应症上市申请获美国FDA受理，8月31日股价下跌0.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663071350","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663071350?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:44","pubTimestamp":1788169497,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，迪哲医药报收于58.28元，较前一交易日下跌0.66%，最新总市值为271.1亿元。该股当日开盘57.87元，最高59.58元，最低57.5元，成交额达3.55亿元，换手率为1.32%。迪哲医药近日披露公告，公司自主研发的舒沃哲新增适应症上市申请已获美国FDA受理，拟用于一线治疗EGFR exon20ins的局部晚期或转移性非小细胞肺癌成人患者。该适应症在中国也已获NMPA受理并纳入优先审评，此前已获中美突破性疗法认定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100024818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1515","159938","BK0239","09939","BK1574","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662034757","title":"迪哲医药(688192.SH)重新向香港联交所递交H股发行上市申请并刊发申请资","url":"https://stock-news.laohu8.com/highlight/detail?id=2662034757","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662034757?lang=zh_cn&edition=full","pubTime":"2026-08-28 08:25","pubTimestamp":1787876738,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)发布公告，公司于2026年8月27日重新向香港联合交易所有限公司(以下简称“香港联交所”)递交了发行H股股票并在香港联交所主板挂牌上市的申请，并于同日在香港联交所网站刊登了本次发行上市的申请材料。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487677.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688192","BK1515","BK1161","09939","BK0239","159938","IPOS","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661110862","title":"每周股票复盘：迪哲医药（688192）股东户数增18.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661110862","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661110862?lang=zh_cn&edition=full","pubTime":"2026-08-23 02:53","pubTimestamp":1787424789,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，迪哲医药报收于59.0元，较上周的60.91元下跌3.14%。本周，迪哲医药8月18日盘中最高价报62.65元。公司公告汇总：公司与阿斯利康签署许可协议，授予舒沃哲全球独家开发和商业化权利，获得6亿美元首付款。股本股东变化截至2026年6月30日，公司股东户数为1.29万户，较3月31日增加2041户，增幅18.73%。户均持股数量由上期的4.26万股减少至3.6万股，户均持股市值为143.58万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK0239","159938","09939","BK1574","BK1161","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661303296","title":"迪哲医药（688192）披露舒沃哲两项非小细胞肺癌临床研究数据获选2026年世界肺癌大会展示，8月21日股价下跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661303296","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661303296?lang=zh_cn&edition=full","pubTime":"2026-08-21 22:15","pubTimestamp":1787321724,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，迪哲医药报收于59.0元，较前一交易日下跌5.07%，最新总市值为274.45亿元。该股当日开盘60.45元，最高61.1元，最低58.1元，成交额达5.38亿元，换手率为1.96%。近日，迪哲医药发布自愿披露公告，其自主研发的舒沃哲两项非小细胞肺癌领域的最新临床研究数据获选在2026年世界肺癌大会上以壁报形式展示。目前相关适应症尚处临床试验阶段，存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100045408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239","BK1574","159938","BK1161","BK1515","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659175175","title":"每周股票复盘：迪哲医药（688192）拟调整董事会人数至7人","url":"https://stock-news.laohu8.com/highlight/detail?id=2659175175","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659175175?lang=zh_cn&edition=full","pubTime":"2026-08-16 01:50","pubTimestamp":1786816223,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，迪哲医药报收于60.91元，较上周的56.0元上涨8.77%。本周，迪哲医药8月13日盘中最高价报63.66元。迪哲医药当前最新总市值283.33亿元，在化学制药板块市值排名15/149，在两市A股市值排名704/5207。本周关注点公司公告汇总：迪哲医药拟调整董事会人数为7人，并选举第三届董事会成员。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000322.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239","BK1515","BK1574","BK1161","159938","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656855286","title":"迪哲医药（688192）披露召开2026年第三次临时股东会的通知，8月4日股价上涨1.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656855286","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656855286?lang=zh_cn&edition=full","pubTime":"2026-08-04 22:17","pubTimestamp":1785853035,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘，迪哲医药报收于50.26元，较前一交易日上涨1.68%，最新总市值为233.79亿元。该股当日开盘50.4元，最高51.9元，最低49.78元，成交额达4.58亿元，换手率为1.96%。近日，迪哲（江苏）医药股份有限公司发布《关于召开2026年第三次临时股东会的通知》。公告显示，公司将于2026年8月20日召开2026年第三次临时股东会，会议采用现场投票与网络投票相结合的方式，股权登记日为2026年8月14日。中小投资者对董事选举议案将单独计票。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400041398.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239","BK1161","BK1515","BK1574","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656196943","title":"每周股票复盘：迪哲医药（688192）与阿斯利康签署授权许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2656196943","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656196943?lang=zh_cn&edition=full","pubTime":"2026-08-02 03:17","pubTimestamp":1785611830,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，迪哲医药报收于51.05元，较上周的55.6元下跌8.18%。本周，迪哲医药7月27日盘中最高价报57.3元。本周关注点公司公告汇总：迪哲医药股东大会通过与阿斯利康签署授权许可协议的议案，获99.9536%同意票。议案获普通股股东同意票186,456,608股，占比99.9536%，中小投资者同意比例为99.4234%。北京市中伦律师事务所出具法律意见书，确认会议召集、召开程序及表决结果合法有效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200001044.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","159938","688192","09939","BK0239","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655805121","title":"迪哲医药（688192）披露与阿斯利康签署授权许可协议暨关联交易议案获通过，7月30日股价下跌4.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655805121","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655805121?lang=zh_cn&edition=full","pubTime":"2026-07-30 22:17","pubTimestamp":1785421034,"startTime":"0","endTime":"0","summary":"截至2026年7月30日收盘，迪哲医药报收于51.16元，较前一交易日下跌4.07%，最新总市值为237.98亿元。近日，迪哲（江苏）医药股份有限公司召开2026年第二次临时股东会，审议通过《关于与阿斯利康签署授权许可协议暨关联交易的议案》。会议于2026年7月30日以现场和网络投票方式召开，出席会议股东188人，代表表决权40.1024%。议案获普通股股东同意票186,456,608股，占比99.9536%，中小投资者对该议案同意比例为99.4234%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000039620.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688192","09939","BK1515","BK1574","BK0239","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654105253","title":"每周股票复盘：迪哲医药（688192）获6亿美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2654105253","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654105253?lang=zh_cn&edition=full","pubTime":"2026-07-26 01:12","pubTimestamp":1784999531,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，迪哲医药报收于55.6元，较上周的61.42元下跌9.48%。本周，迪哲医药7月22日盘中最高价报65.9元。本周关注点来自业绩披露要点：迪哲医药预计2026年上半年营收5.22亿元，同比增长约47.04%。来自公司公告汇总：迪哲医药拟授予阿斯利康舒沃哲全球独家权利，获6亿美元首付款。来自业绩披露要点：归属于母公司净亏损约2.1亿元，同比减少44.35%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000098.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","159938","09939","688192","BK1161","BK0239","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653746090","title":"迪哲医药(688192.SH)发预亏，预计半年度归母净亏损2.1亿元左右","url":"https://stock-news.laohu8.com/highlight/detail?id=2653746090","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653746090?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:20","pubTimestamp":1784802006,"startTime":"0","endTime":"0","summary":"预计2026年半年度归属于母公司所有者的扣除非经常性损益后的净亏损2.31亿元左右，同比亏损减少44.90%左右。公司2026年半年度营业收入大幅增长，同时产品研发进展较为顺利，研发投入仍保持较高水平，预计2026年半年度将继续出现归属于母公司所有者的净利润为负的情况，但公司主营业务、核心竞争力没有发生重大不利变化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688192","159938","BK1161","BK1574","BK0239","09939","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653718648","title":"新股消息 | 迪哲医药(688192.SH)港股IPO招股书失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2653718648","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653718648?lang=zh_cn&edition=full","pubTime":"2026-07-23 10:44","pubTimestamp":1784774673,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，迪哲(江苏)医药股份有限公司(简称：迪哲医药(688192.SH))于2026年1月23日所递交的港股招股书满6个月，于2026年7月23日失效，递表时高盛和华泰国际为其联席保荐人。据招股书，迪哲医药是一家处于商业化阶段的生物制药公司，公司的核心治疗领域是肿瘤及血液系统疾病。公司的上市产品舒沃哲®是全球范围内唯一获批用于治疗EGFR 20号外显子插入突变型肺癌的小分子表皮生长因子受体酪氨酸激酶抑制剂。于2023年度、2024年度、2025年截至9月30日止九个月，该公司实现收入分别为9128.9万元、3.6亿元、5.86亿元人民币。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471260.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK0239","BK4585","09939","BK1574","FRHC","BK4127","KCAI","KCE","BK4588","BK1161","REDS","159938","IPOS","BK1515","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653676503","title":"迪哲医药（688192）披露拟与阿斯利康签署舒沃哲®全球许可协议，7月22日股价下跌1.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653676503","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653676503?lang=zh_cn&edition=full","pubTime":"2026-07-22 22:14","pubTimestamp":1784729661,"startTime":"0","endTime":"0","summary":"截至2026年7月22日收盘，迪哲医药报收于60.86元，较前一交易日下跌1.49%，最新总市值为283.1亿元。该股当日开盘60.1元，最高65.9元，最低60.1元，成交额达11.57亿元，换手率为3.96%。近日，迪哲医药披露公告，拟与阿斯利康签署《许可协议》，授予其全球范围内独家开发、商业化舒沃哲的权利。阿斯利康为公司关联法人，本次交易构成关联交易，但不构成重大资产重组。该事项已获董事会审议通过，尚需提交股东会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200047313.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239","BK1161","BK1515","159938","09939","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652237196","title":"每周股票复盘：迪哲医药（688192）与阿斯利康签6亿美元协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2652237196","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652237196?lang=zh_cn&edition=full","pubTime":"2026-07-19 01:31","pubTimestamp":1784395867,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，迪哲医药报收于61.42元，较上周的46.76元上涨31.35%。本周，迪哲医药7月16日盘中最高价报69.58元。来自公司公告汇总：迪哲医药与阿斯利康签署授权许可协议，获6亿美元首付款。公司公告汇总迪哲（江苏）医药股份有限公司与阿斯利康签署《许可协议》，授予其全球范围内独家开发、商业化舒沃哲的权利。迪哲医药发布股票交易异常波动公告，2026年7月13日至15日连续三日收盘价涨幅偏离值累计达30%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000254.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1515","09939","BK0239","BK1161","BK1574","688192"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791942684781,"stockEarnings":[{"period":"1week","weight":0.0671},{"period":"1month","weight":0.1664},{"period":"3month","weight":-0.0843},{"period":"6month","weight":0.0139},{"period":"1year","weight":-0.072},{"period":"ytd","weight":0.0747}],"compareEarnings":[{"period":"1week","weight":-0.0108},{"period":"1month","weight":-0.0224},{"period":"3month","weight":-0.0391},{"period":"6month","weight":-0.0628},{"period":"1year","weight":-0.0228},{"period":"ytd","weight":-0.0423}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"迪哲(江苏)医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"12936人(较上一季度增加18.73%)","perCapita":"35653股","listingDate":"2021-12-10","address":"江苏省无锡市新吴区和风路26号汇融商务广场C栋404、405、416室","registeredCapital":"46516万元","survey":" 迪哲(江苏)医药股份有限公司的主营业务是专注于肿瘤、血液系统疾病领域创新疗法的研究、开发和商业化。公司的主要产品是舒沃哲、高瑞哲。公司获第七批国家级专精特新“小巨人”企业认定。此外，公司首款源头创新产品舒沃哲的研发及产业化项目，荣获江苏省科技进步奖一等奖。","listedPrice":52.58},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迪哲医药-U(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迪哲医药-U(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迪哲医药-U,688192,迪哲医药-U股票,迪哲医药-U股票老虎,迪哲医药-U股票老虎国际,迪哲医药-U行情,迪哲医药-U股票行情,迪哲医药-U股价,迪哲医药-U股市,迪哲医药-U股票价格,迪哲医药-U股票交易,迪哲医药-U股票购买,迪哲医药-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迪哲医药-U(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迪哲医药-U(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}